Reacción a "Two clinical trials test immunomodulator to improve cancer immunotherapy"

The studies are very interesting from a preclinical point of view and of great translational value for the future. The methodology used is very novel. However, the clinical part is still weak due to the small number of patients included. 

It is a further demonstration that boosting the action of T lymphocytes increases the response to immunotherapy treatments against cancer.